Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

Alison L. Hill, Daniel I S Rosenbloom, Feng Fu, Martin A. Nowak, Robert F Siliciano

Research output: Contribution to journalArticle

Abstract

Massive research efforts are now underway to develop a cure for HIV infection, allowing patients to discontinue lifelong combination antiretroviral therapy (ART). New latency-reversing agents (LRAs) may be able to purge the persistent reservoir of latent virus in resting memory CD4+ T cells, but the degree of reservoir reduction needed for cure remains unknown. Here we use a stochastic model of infection dynamics to estimate the efficacy of LRA needed to prevent viral rebound after ART interruption. We incorporate clinical data to estimate population-level parameter distributions and outcomes. Our findings suggest that ?2,000-fold reductions are required to permit a majority of patients to interrupt ART for 1 y without rebound and that rebound may occur suddenly after multiple years. Greater than 10,000-fold reductions may be required to prevent rebound altogether. Our results predict large variation in rebound times following LRA therapy, which will complicate clinical management. This model provides benchmarks for moving LRAs from the laboratory to the clinic and can aid in the design and interpretation of clinical trials. These results also apply to other interventions to reduce the latent reservoir and can explain the observed return of viremia after months of apparent cure in recent bone marrow transplant recipients and an immediately-treated neonate.

Original languageEnglish (US)
Pages (from-to)13475-13480
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number37
DOIs
StatePublished - Sep 16 2014

Fingerprint

HIV-1
Benchmarking
Viremia
Therapeutics
HIV Infections
Bone Marrow
Clinical Trials
Newborn Infant
Viruses
T-Lymphocytes
Infection
Research
Population

ASJC Scopus subject areas

  • General

Cite this

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. / Hill, Alison L.; Rosenbloom, Daniel I S; Fu, Feng; Nowak, Martin A.; Siliciano, Robert F.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 37, 16.09.2014, p. 13475-13480.

Research output: Contribution to journalArticle

Hill, Alison L. ; Rosenbloom, Daniel I S ; Fu, Feng ; Nowak, Martin A. ; Siliciano, Robert F. / Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 37. pp. 13475-13480.
@article{b2d3fdeccb1b4e5f94bfd4e5bdf58e2d,
title = "Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1",
abstract = "Massive research efforts are now underway to develop a cure for HIV infection, allowing patients to discontinue lifelong combination antiretroviral therapy (ART). New latency-reversing agents (LRAs) may be able to purge the persistent reservoir of latent virus in resting memory CD4+ T cells, but the degree of reservoir reduction needed for cure remains unknown. Here we use a stochastic model of infection dynamics to estimate the efficacy of LRA needed to prevent viral rebound after ART interruption. We incorporate clinical data to estimate population-level parameter distributions and outcomes. Our findings suggest that ?2,000-fold reductions are required to permit a majority of patients to interrupt ART for 1 y without rebound and that rebound may occur suddenly after multiple years. Greater than 10,000-fold reductions may be required to prevent rebound altogether. Our results predict large variation in rebound times following LRA therapy, which will complicate clinical management. This model provides benchmarks for moving LRAs from the laboratory to the clinic and can aid in the design and interpretation of clinical trials. These results also apply to other interventions to reduce the latent reservoir and can explain the observed return of viremia after months of apparent cure in recent bone marrow transplant recipients and an immediately-treated neonate.",
author = "Hill, {Alison L.} and Rosenbloom, {Daniel I S} and Feng Fu and Nowak, {Martin A.} and Siliciano, {Robert F}",
year = "2014",
month = "9",
day = "16",
doi = "10.1073/pnas.1406663111",
language = "English (US)",
volume = "111",
pages = "13475--13480",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "37",

}

TY - JOUR

T1 - Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1

AU - Hill, Alison L.

AU - Rosenbloom, Daniel I S

AU - Fu, Feng

AU - Nowak, Martin A.

AU - Siliciano, Robert F

PY - 2014/9/16

Y1 - 2014/9/16

N2 - Massive research efforts are now underway to develop a cure for HIV infection, allowing patients to discontinue lifelong combination antiretroviral therapy (ART). New latency-reversing agents (LRAs) may be able to purge the persistent reservoir of latent virus in resting memory CD4+ T cells, but the degree of reservoir reduction needed for cure remains unknown. Here we use a stochastic model of infection dynamics to estimate the efficacy of LRA needed to prevent viral rebound after ART interruption. We incorporate clinical data to estimate population-level parameter distributions and outcomes. Our findings suggest that ?2,000-fold reductions are required to permit a majority of patients to interrupt ART for 1 y without rebound and that rebound may occur suddenly after multiple years. Greater than 10,000-fold reductions may be required to prevent rebound altogether. Our results predict large variation in rebound times following LRA therapy, which will complicate clinical management. This model provides benchmarks for moving LRAs from the laboratory to the clinic and can aid in the design and interpretation of clinical trials. These results also apply to other interventions to reduce the latent reservoir and can explain the observed return of viremia after months of apparent cure in recent bone marrow transplant recipients and an immediately-treated neonate.

AB - Massive research efforts are now underway to develop a cure for HIV infection, allowing patients to discontinue lifelong combination antiretroviral therapy (ART). New latency-reversing agents (LRAs) may be able to purge the persistent reservoir of latent virus in resting memory CD4+ T cells, but the degree of reservoir reduction needed for cure remains unknown. Here we use a stochastic model of infection dynamics to estimate the efficacy of LRA needed to prevent viral rebound after ART interruption. We incorporate clinical data to estimate population-level parameter distributions and outcomes. Our findings suggest that ?2,000-fold reductions are required to permit a majority of patients to interrupt ART for 1 y without rebound and that rebound may occur suddenly after multiple years. Greater than 10,000-fold reductions may be required to prevent rebound altogether. Our results predict large variation in rebound times following LRA therapy, which will complicate clinical management. This model provides benchmarks for moving LRAs from the laboratory to the clinic and can aid in the design and interpretation of clinical trials. These results also apply to other interventions to reduce the latent reservoir and can explain the observed return of viremia after months of apparent cure in recent bone marrow transplant recipients and an immediately-treated neonate.

UR - http://www.scopus.com/inward/record.url?scp=84907240033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907240033&partnerID=8YFLogxK

U2 - 10.1073/pnas.1406663111

DO - 10.1073/pnas.1406663111

M3 - Article

C2 - 25097264

AN - SCOPUS:84907240033

VL - 111

SP - 13475

EP - 13480

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 37

ER -